سعر انكريسينك 25/45 مجم 7 اقراص 2026

Incresync 25 mg/45 mg tablets (Takeda), pack of 7: fixed-dose combination of alogliptin (DPP-4 inhibitor) and pioglitazone (thiazolidinedione) for type 2 diabetes mellitus.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (not for type 1 diabetes).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Second- or third-line treatment in adults with type 2 diabetes inadequately controlled on pioglitazone alone when metformin is inappropriate, or in triple therapy with metformin and pioglitazone; or to replace separate alogliptin and pioglitazone tablets.Population: Adults 18 years and olderEuropean Medicines Agency (EMA)

• Serious adverse reactions include congestive heart failure, pancreatitis, hypersensitivity, hepatic effects, oedema, fractures and bladder tumours.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Initiation in patients with established NYHA class III or IV heart failure; history of serious hypersensitivity to alogliptin, pioglitazone or excipients (US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity (including to any DPP-4 inhibitor); cardiac failure or history of cardiac failure (NYHA I-IV); hepatic impairment; diabetic ketoacidosis; current or past bladder cancer; uninvestigated macroscopic haematuria (EU SmPC).International label, same product · European Medicines Agency (EMA)

• Boxed warning: thiazolidinediones, including pioglitazone, cause or exacerbate congestive heart failure; monitor for weight gain, dyspnoea and oedema after initiation and dose increases; not recommended in symptomatic heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: pancreatitis, hypersensitivity reactions, hepatic effects, oedema, fractures, urinary bladder tumours, hypoglycaemia with insulin or insulin secretagogues, macular oedema, severe arthralgia and bullous pemphigoid.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Insulin and insulin secretagogues (e.g., sulfonylureas)Increased risk of hypoglycaemia; lower doses of insulin or secretagogue may be required.DailyMed (U.S. National Library of Medicine)
• Strong CYP2C8 inhibitors (e.g., gemfibrozil)Increase pioglitazone concentrations; limit pioglitazone to 15 mg daily.DailyMed (U.S. National Library of Medicine)
• CYP2C8 inducers (e.g., rifampin)May decrease pioglitazone concentrations.DailyMed (U.S. National Library of Medicine)

• Limited data are insufficient to inform a drug-associated risk; poorly controlled diabetes carries maternal and fetal risks; no adverse developmental effects in animal studies at relevant exposures (US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Incresync should not be used during pregnancy (animal studies of the combination showed reproductive toxicity) (EU SmPC).International label, same product · European Medicines Agency (EMA)
• No information on presence in human milk; both are present in rat milk; weigh benefits of breastfeeding against clinical need (US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Alogliptin: Inhibits DPP-4, slowing inactivation of incretin hormones (GLP-1, GIP) and increasing glucose-dependent insulin secretion.
• Pioglitazone: PPAR-gamma agonist that decreases insulin resistance in peripheral tissues and the liver; depends on the presence of insulin.